Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? - Wikidata - wikimedia - TriplyDB

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

http://www.wikidata.org/entity/Q26863707

about

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies Biosimilars of low-molecular-weight heparin products: fostering competition or reducing 'biodiversity'?Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs.Biosimilar Insulin and Costs: What Can We Expect?Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.Key drivers for market penetration of biosimilars in Europe.Novel products for haemostasis.Can biosimilars help achieve the goals of US health care reform?The Challenging Future of the Biosimilars Market.What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences.Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.Introduction of biosimilar insulins in Europe.Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.Drug tendering: drug supply and shortage implications for the uptake of biosimilars Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis The role of biosimilars in value-based oncology care

P2860

Q26738325-80F11767-0C5A-4582-A79C-EA6F9EB70F96 Q35880101-2D75B2B0-DAA1-4017-B7E2-FD0671D9D986 Q36284094-563295E1-3C09-4FC2-B069-2B930A1054FC Q36638889-65A1CBE7-C77C-47F6-A40C-FCE59BABB460 Q37474361-7E55CA11-A4BC-4811-9636-622C055F5031 Q37598156-67538F8B-3D13-49E0-8EF5-8FD850B01271 Q37669625-6DC9D348-F263-457F-99C0-29A432877F8D Q38206850-6786984B-3151-49F4-BEA5-C337BC8ABC91 Q38670950-9571F9B2-27E0-43A9-8984-225ED029DD9F Q38832419-1970049E-5B3C-40ED-B944-E67C7A07B6DC Q38841536-43E81A7F-0C62-4C62-82EE-4FB65D7B525A Q38893192-FBEC3F0C-2A0B-4101-9C60-3AB63669A57C Q39059388-9AFB16E6-7853-4BAC-AC44-F3011095B528 Q39368850-ACA036D8-A0AB-47D7-ADB6-53A2A4D30EAB Q39403982-9BEFEFE3-B73E-4499-9B94-43BEBC991C7A Q39455869-032A92B3-1E77-413C-806C-A6E26882385A Q42370596-6CEE6588-D181-4270-9339-F9780DAE12AF Q46086372-81DB1835-34C6-478A-A370-200FBB8EE2BE Q50483003-7DBF9CB5-6BA1-4891-A850-42F162D497DF Q51022840-1EB21DBB-62D5-40EF-A3A2-E0C463EB15E1 Q57191804-E9D18C9A-619D-41DF-A400-1C5DEFF8F0EE Q58605622-57A3ED58-B9C1-4FAF-93D9-2C451A01C4F2

P2860

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

http://www.wikidata.org/entity/Q26863707

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@ast

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@en

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@nl

type

label

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@ast

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@en

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@nl

prefLabel

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@ast

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@en

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@nl

P1433

Q26863707-4FA7BB4E-2496-4933-AC38-FF42D5710066

P1476

Q26863707-EE9CBEA9-B4AA-4116-8D08-4262F8E6C432

P2093

Q26863707-0FC9D85A-7928-4645-ABF6-D7867699EA26

Q26863707-2DC9003B-1877-4D4F-91F1-6D21CF599DF3

Q26863707-3CAADE9F-BB79-4307-BE57-AF2D076E27DF

Q26863707-CB120753-BABC-4B92-99B9-78A2EE109B11

Q26863707-DCDA6B7F-BB1E-4A66-B5DE-664838441AE9

P2860

Q26863707-0876DE67-CBDE-4EFC-A95C-55FAAA35581A

Q26863707-0D0FA41B-D393-4482-82E7-DD7AD3CD8523

Q26863707-0F8D26E8-C1CC-4ACF-B582-1E25E35D8944

Q26863707-0FF8C326-7ED0-46A8-B026-B6B02700A992

Q26863707-3144595E-CC26-44FE-BCB8-4704192E23D7

Q26863707-57B44ABF-A066-4A35-B9BF-E6BBC7973E20

Q26863707-77CE69DA-5FFC-4B09-9AD1-1B7A56B016F6

Q26863707-986E2DB6-81DB-4096-872A-CBBD5E755C3A

Q26863707-9D0B58C1-7F45-4FCE-8585-0B754A3EB580

Q26863707-BBAA1E18-81FE-4052-BF58-1810D97A2197

P2888

Q26863707-9CEB892A-8D6C-47F6-B0EE-EB5F0161B715

P304

Q26863707-397C4582-5650-4E96-AC84-8918CC76D72C

P31

Q26863707-47e75139-a585-424b-8026-0a419f590630

Q26863707-DA0AC1E8-458F-4A2F-88FE-70FB33BA900C

P3181

Q26863707-4CA59272-6ED9-479E-8858-4591C9F6F800

P356

Q26863707-87476B35-4AEC-416D-B51A-F5EE429C756D

P407

Q26863707-CA0DEEEE-3945-44C6-980F-EE482BB17C02

P433

Q26863707-666F1C0D-9CDF-4D23-ADB1-C1C32FA35E8C

P478

Q26863707-DBA4A317-9AB0-4146-B5C4-C2C001CE86B8

P577

Q26863707-296AF50A-8AA7-40A4-8330-9A103E3851DC

P5875

Q26863707-F0254F4A-D1CB-40C7-BAA1-605E6CB188AD

P6179

Q26863707-2BEA8651-701A-4D87-9909-3B60FE82B29A

P698

Q26863707-D78D709A-BEA6-4DD6-BB52-77F2D6A4E466

P932

Q26863707-E39BBB90-6337-4357-91C9-8C831C326E47

P3181

P356

S10198-013-0538-4

P1433

The European Journal of Health Economics

P1476

Are biosimilars the next tool ...... r pharmaceutical expenditures?

@en

P2093

Frank Hulstaert

http://www.w3.org/2001/XMLSchema#string

Irmgard Vinck

http://www.w3.org/2001/XMLSchema#string

Isabelle Lepage-Nefkens

http://www.w3.org/2001/XMLSchema#string

María-Isabel Farfan-Portet

http://www.w3.org/2001/XMLSchema#string

Sophie Gerkens

http://www.w3.org/2001/XMLSchema#string

P2860

Biosimilar medicines and cost-effectiveness.

The economic pressures for biosimilar drug use in cancer medicine

Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

Biosimilars: evidential standards for health technology assessment.

Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.

Biosimilars and market access: a question of comparability and costs?

Projecting future drug expenditures--2012.

Projecting future drug expenditures: 2011.

Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals.

Biosimilars 2.0: guiding principles for a global "patients first" standard.

P2888

s10198-013-0538-4

P304

223-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

430573

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S10198-013-0538-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258854925

http://www.w3.org/2001/XMLSchema#string

P6179

1049966889

http://www.w3.org/2001/XMLSchema#string

P698

24271016

http://www.w3.org/2001/XMLSchema#string

P932

3950601

http://www.w3.org/2001/XMLSchema#string